Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Adverse Events and Resistant Mechanism of Eribulin Combined With or Without Bevacizumab for Advanced HER2 Negative Breast Cancer Patients, an Open-label, Randomized, Multi-center PhaseⅡ Clinical Trial.

NCT06539559 is registered in ClinicalTrials.gov with Wang Jiayu as lead sponsor.

NCT NCT06539559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06539559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Adverse Events and Resistant Mechanism of Eribulin Combined With or Without Bevacizumab for Advanced HER2 Negative Breast Cancer Patients, an Open-label, Randomized, Multi-center PhaseⅡ Clinical Trial.
Lead sponsor
Wang Jiayu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2024
Completion date
August 1, 2026
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab, breast neoplasms, drug therapy, neoplasm metastasis